283 related articles for article (PubMed ID: 23856973)
1. Therapeutic effects of thalidomide in hematologic disorders: a review.
Xu M; Hou Y; Sheng L; Peng J
Front Med; 2013 Sep; 7(3):290-300. PubMed ID: 23856973
[TBL] [Abstract][Full Text] [Related]
2. [Thalidomide: mechanisms of action and new insights in hematology].
Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T
Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258
[TBL] [Abstract][Full Text] [Related]
3. [IMiDs in hematology].
Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
[TBL] [Abstract][Full Text] [Related]
4. Current status of thalidomide in the treatment of cancer.
Rajkumar SV
Oncology (Williston Park); 2001 Jul; 15(7):867-74; discussion 877-9. PubMed ID: 11499688
[TBL] [Abstract][Full Text] [Related]
5. [Lenalidomide in hematological malignancies---review].
Jin X; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):205-9. PubMed ID: 22391198
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide in cancer medicine.
Eleutherakis-Papaiakovou V; Bamias A; Dimopoulos MA
Ann Oncol; 2004 Aug; 15(8):1151-60. PubMed ID: 15277253
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic therapy in hematologic malignancies.
Moehler TM; Hillengass J; Goldschmidt H; Ho AD
Curr Pharm Des; 2004; 10(11):1221-34. PubMed ID: 15078137
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide in the treatment of plasma cell malignancies.
Rajkumar SV; Kyle RA
J Clin Oncol; 2001 Aug; 19(16):3593-5. PubMed ID: 11504740
[No Abstract] [Full Text] [Related]
9. [Thalidomide: new uses for an old drug].
Wu KL; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.
Ribatti D; Vacca A
Leukemia; 2005 Sep; 19(9):1525-31. PubMed ID: 15973447
[TBL] [Abstract][Full Text] [Related]
11. Trials investigate first-line thalidomide in multiple myeloma.
Owen OG
Lancet Oncol; 2005 Jan; 6(1):6. PubMed ID: 15672486
[No Abstract] [Full Text] [Related]
12. Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.
Wechalekar AD; Chen CI; Sutton D; Reece D; Voralia M; Stewart AK
Leuk Lymphoma; 2003 Jul; 44(7):1147-9. PubMed ID: 12916866
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions.
Desikan RK; Jagannath S
Semin Oncol; 2001 Dec; 28(6):593-6. PubMed ID: 11740815
[TBL] [Abstract][Full Text] [Related]
14. Current role of thalidomide in cancer treatment.
Thomas DA; Kantarjian HM
Curr Opin Oncol; 2000 Nov; 12(6):564-73. PubMed ID: 11085456
[TBL] [Abstract][Full Text] [Related]
15. [Dynamic contrast-enhanced MRI for evaluating bone marrow microcirculation in malignant hematological diseases before and after thalidomide therapy].
Scherer A; Strupp C; Wittsack HJ; Engelbrecht V; Willers R; Germing U; Gattermann N; Haas R; Mödder U
Radiologe; 2002 Mar; 42(3):222-30. PubMed ID: 11963240
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide in multiple myeloma.
Rajkumar SV
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):11-6. PubMed ID: 11204667
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.
Breitkreutz I; Anderson KC
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):973-85. PubMed ID: 18624684
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers.
Bertolini F; Mingrone W; Alietti A; Ferrucci PF; Cocorocchio E; Peccatori F; Cinieri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G
Ann Oncol; 2001 Jul; 12(7):987-90. PubMed ID: 11521807
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease.
Rajkumar SV
Semin Hematol; 2003 Oct; 40(4 Suppl 4):17-22. PubMed ID: 15015892
[TBL] [Abstract][Full Text] [Related]
20. Haematological cancer: a step before the next leap?
Vij R
Nat Rev Clin Oncol; 2013 Nov; 10(11):610-2. PubMed ID: 24101121
[No Abstract] [Full Text] [Related]
[Next] [New Search]
